Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#91 / 200 Total
AE - Adams Resources & Energy Inc. - Stock Price Chart
TickerAE [AMEX]
CompanyAdams Resources & Energy Inc.
CountryUSA
IndustryOil & Gas Refining & Marketing
Market Cap76.22MEPS (ttm)-1.93
P/E-EPS this Y-242.65%
Forward P/E47.44EPS next Y143.30%
PEG-EPS past 5Y-
P/S0.03EPS next 5Y-
P/B0.81EPS Q/Q77.32%
Dividend3.21%Sales Q/Q-10.82%
Insider Own2.19%Inst Own58.52%
Insider Trans0.41%Inst Trans-2.95%
Short Float0.44%EarningsNov 08/a
Analyst Recom1.00Target Price44.50
Avg Volume9.38K52W Range22.67 - 59.05
Adams Resources & Energy, Inc. engages in the business of crude oil marketing, transportation and storage in various crude oil and natural gas basins. It operates through the following segments: crude oil marketing, transportation and storage, tank truck transportation of liquid chemicals, pressurized gases, asphalt and dry bulk, and pipeline transportation, terminalling and storage of crude oil. The company was founded by Kenneth Stanley Adams, Jr. in 1947 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leggio Michael F IIIChief Operating OfficerDec 14Buy25.771904,8972,401Dec 14 04:21 PM
Harrison Wade MPresident, Service TransportDec 13Buy25.81401,0322,303Dec 13 04:18 PM
Bosard Trey TPresident, Phoenix Oil, Inc.Aug 14Option Exercise0.005,08605,686Aug 14 05:34 PM
Leggio Michael F IIIChief Operating OfficerJun 16Buy35.701404,9982,211Jun 20 05:10 PM
Dominic Dennis E.DirectorMay 22Buy33.771,00033,7703,886May 22 06:55 PM
NOVA - Sunnova Energy International Inc - Stock Price Chart
TickerNOVA [NYSE, RUT]
CompanySunnova Energy International Inc
CountryUSA
IndustrySolar
Market Cap891.65MEPS (ttm)-3.51
P/E-EPS this Y32.06%
Forward P/E-EPS next Y10.86%
PEG-EPS past 5Y-17.44%
P/S1.24EPS next 5Y-14.00%
P/B0.58EPS Q/Q-742.66%
Dividend-Sales Q/Q-0.72%
Insider Own13.29%Inst Own110.58%
Insider Trans0.95%Inst Trans7.10%
Short Float32.32%EarningsFeb 21/a
Analyst Recom1.52Target Price19.06
Avg Volume6.92M52W Range6.49 - 24.56
Sunnova Energy International, Inc. is an energy services company, which engages in the provision of responsive energy management solutions. The firm also offers solar energy products and services. The company was founded by William Jackson Berger in 2012 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mohamed AkbarDirectorFeb 28Buy6.92152,4501,054,954236,139Feb 28 05:35 PM
Searle DavidSee Remarks.Feb 21Option Exercise0.005,90305,903Feb 23 01:37 PM
Mathews Paul SSee RemarksJan 31Option Exercise0.001,71101,711Feb 02 10:06 AM
Berger William JSee RemarksAug 01Sale17.8647,150841,991365,222Aug 01 08:20 PM
Berger William JSee RemarksJul 29Option Exercise0.00119,0470412,372Aug 01 08:20 PM
EAF - GrafTech International Ltd. - Stock Price Chart
TickerEAF [NYSE, RUT]
CompanyGrafTech International Ltd.
CountryUSA
IndustryElectrical Equipment & Parts
Market Cap452.02MEPS (ttm)-0.99
P/E-EPS this Y64.41%
Forward P/E110.97EPS next Y104.50%
PEG-EPS past 5Y-
P/S0.73EPS next 5Y-5.87%
P/B5.78EPS Q/Q-531.50%
Dividend0.57%Sales Q/Q-44.59%
Insider Own19.00%Inst Own74.37%
Insider Trans-30.53%Inst Trans1.19%
Short Float6.06%EarningsFeb 14/b
Analyst Recom3.00Target Price1.75
Avg Volume4.02M52W Range1.18 - 5.82
GrafTech International Ltd. engages in the manufacture of graphite electrode products essential to the production of electric arc furnace steel and other ferrous and non-ferrous metals. The firm also produces a needle coke product which is a raw material in producing graphite electrodes. Its customers include steel producers and other ferrous and non-ferrous metal producers in Europe, the Middle East and Africa, the Americas and Asia-Pacific, which sell its products into the automotive, construction, appliance, machinery, equipment, and transportation industries. The company was founded in 1886 and is headquartered in Brooklyn Heights, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BCP GP LtdFormer 10% OwnerJan 02Sale2.203,922,7868,630,12923,352,826Jan 04 08:32 PM
BCP GP LtdFormer 10% OwnerJan 02Sale2.203,922,7868,630,12923,352,826Jan 04 08:27 PM
BCP GP LtdFormer 10% OwnerJan 02Sale2.203,922,7868,630,12923,352,826Jan 04 08:23 PM
BCP GP Ltd10% OwnerDec 29Sale2.22129,022285,96427,275,612Dec 29 09:31 PM
BCP GP Ltd10% OwnerDec 29Sale2.22129,022285,96427,275,612Dec 29 09:34 PM
BAND - Bandwidth Inc - Stock Price Chart
TickerBAND [NASD, RUT]
CompanyBandwidth Inc
CountryUSA
IndustrySoftware - Infrastructure
Market Cap526.65MEPS (ttm)-0.65
P/E-EPS this Y62.38%
Forward P/E12.94EPS next Y17.81%
PEG-EPS past 5Y-
P/S0.88EPS next 5Y26.80%
P/B1.88EPS Q/Q-160.65%
Dividend-Sales Q/Q5.36%
Insider Own11.53%Inst Own70.48%
Insider Trans-1.22%Inst Trans-4.32%
Short Float7.80%EarningsFeb 28/b
Analyst Recom2.00Target Price20.57
Avg Volume344.29K52W Range9.34 - 18.89
Bandwidth, Inc. engages in the provision of cloud communications software services. The firm is also involved in delivering experiences through voice calling, text messaging, and emergency services applications. The company was founded by Henry Kaestner and David A. Morken in July 2000 and is headquartered in Raleigh, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Asbill Richard BrandonGeneral CounselJan 19Sale13.215036,64417,683Jan 22 04:10 PM
Asbill Richard BrandonGeneral CounselJan 18Option Exercise0.001,452018,186Jan 22 04:10 PM
Morken David A.Chairman & CEOJan 04Sale13.522,58034,88257,390Jan 04 08:51 PM
Raiford DarylChief Financial OfficerJan 04Sale13.581,34018,19234,191Jan 04 08:52 PM
Asbill Richard BrandonGeneral CounselJan 04Sale13.4885411,51216,734Jan 04 08:55 PM
CRDL - Cardiol Therapeutics Inc - Stock Price Chart
TickerCRDL [NASD]
CompanyCardiol Therapeutics Inc
CountryCanada
IndustryDrug Manufacturers - Specialty & Generic
Market Cap134.13MEPS (ttm)-0.32
P/E-EPS this Y10.35%
Forward P/E-EPS next Y-2.22%
PEG-EPS past 5Y-47.09%
P/S-EPS next 5Y-
P/B5.18EPS Q/Q29.93%
Dividend-Sales Q/Q-
Insider Own4.64%Inst Own10.64%
Insider Trans0.00%Inst Trans-
Short Float0.24%EarningsNov 15/b
Analyst Recom1.00Target Price4.31
Avg Volume294.88K52W Range0.45 - 1.92
Feb-21-24 07:27AM Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis (Newsfile) -11.98%
Feb-15-24 07:27AM Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis (Newsfile) +42.31%
Jan-24-24 07:27AM Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market (Newsfile) -5.36%
Jan-09-24 07:27AM Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis (Newsfile)
Dec-05-23 07:27AM Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot (Newsfile)
Nov-16-23 05:30AM Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (Newsfile)
Nov-01-23 07:27AM Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis (Newsfile)
Oct-20-23 05:00PM Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (Newsfile) -6.76%
Oct-13-23 09:24AM Cardiol Therapeutics (NASDAQ: CRDL)Advancements in Therapies for Inflammatory Heart Diseases (News Direct) -18.00%
Oct-11-23 01:05PM Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol (News Direct)
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
SEEL - Seelos Therapeutics Inc - Stock Price Chart
TickerSEEL [NASD]
CompanySeelos Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap17.65MEPS (ttm)-13.39
P/E-EPS this Y98.10%
Forward P/E-EPS next Y-233.75%
PEG-EPS past 5Y53.03%
P/S11.39EPS next 5Y-
P/B-EPS Q/Q138.57%
Dividend-Sales Q/Q-
Insider Own12.15%Inst Own13.05%
Insider Trans10.56%Inst Trans-50.99%
Short Float2.58%EarningsAug 11/b
Analyst Recom1.00Target Price120.00
Avg Volume714.74K52W Range0.71 - 49.80
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehra RajSee RemarksDec 01Buy1.3275,75799,999185,142Dec 01 04:16 PM
Golembiewski Michael JosephChief Financial OfficerNov 30Buy1.2183,000100,22286,450Dec 01 04:16 PM
CIO - City Office REIT Inc - Stock Price Chart
TickerCIO [NYSE, RUT]
CompanyCity Office REIT Inc
CountryCanada
IndustryREIT - Office
Market Cap183.89MEPS (ttm)-0.25
P/E-EPS this Y-116.00%
Forward P/E-EPS next Y-1.85%
PEG-EPS past 5Y-
P/S1.03EPS next 5Y9.00%
P/B0.28EPS Q/Q68.53%
Dividend8.73%Sales Q/Q-0.65%
Insider Own3.99%Inst Own70.48%
Insider Trans0.00%Inst Trans-9.11%
Short Float0.97%EarningsFeb 22/b
Analyst Recom2.20Target Price6.00
Avg Volume298.59K52W Range3.45 - 8.09
City Office REIT, Inc. is a real estate investment trust. It focuses on acquiring, owning and operating office properties located primarily in metropolitan areas in the Southern and Western United States. The company was founded on November 26, 2013 and is headquartered in Vancouver, Canada.
CING - Cingulate Inc - Stock Price Chart
TickerCING [NASD]
CompanyCingulate Inc
CountryUSA
IndustryBiotechnology
Market Cap23.38MEPS (ttm)-32.59
P/E-EPS this Y11.00%
Forward P/E-EPS next Y56.78%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q15.06%
Dividend-Sales Q/Q-
Insider Own13.99%Inst Own0.02%
Insider Trans0.21%Inst Trans-84.75%
Short Float0.76%EarningsNov 13/a
Analyst Recom2.00Target Price21.50
Avg Volume1.69M52W Range1.00 - 38.20
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Callahan Jennifer L.Corporate ControllerSep 15Buy0.675,0003,34845,508Sep 18 06:00 PM
Werth Peter J.DirectorAug 11Buy0.551,823,1551,000,0012,798,320Aug 14 04:38 PM
Callahan Jennifer L.Corporate ControllerMay 15Buy1.012,0002,02040,508May 16 06:00 PM
Callahan Jennifer L.Corporate ControllerMay 12Buy1.084,0004,32038,508May 16 06:00 PM
NKTX - Nkarta Inc - Stock Price Chart
TickerNKTX [NASD, RUT]
CompanyNkarta Inc
CountryUSA
IndustryBiotechnology
Market Cap592.77MEPS (ttm)-2.50
P/E-EPS this Y10.48%
Forward P/E-EPS next Y1.93%
PEG-EPS past 5Y-319.81%
P/S-EPS next 5Y-
P/B2.00EPS Q/Q10.33%
Dividend-Sales Q/Q-
Insider Own46.13%Inst Own58.40%
Insider Trans-0.13%Inst Trans-6.89%
Short Float17.21%EarningsNov 09/a
Analyst Recom1.00Target Price14.29
Avg Volume2.03M52W Range1.28 - 12.20
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trager JamesChief Scientific OfficerFeb 12Sale12.004,14349,716149,415Feb 14 09:12 PM
HASTINGS PAUL JChief Executive OfficerJan 16Sale8.749,69784,752390,507Jan 18 04:40 PM
Trager JamesChief Scientific OfficerJan 16Sale8.744,56039,854153,558Jan 18 04:43 PM
Hager Alicia J.Chief Legal OfficerJan 16Sale8.744,55439,802107,942Jan 18 04:38 PM
Shook DavidChief Medical OfficerJan 16Sale8.743,55231,044114,980Jan 18 04:45 PM
INDP - Indaptus Therapeutics Inc - Stock Price Chart
TickerINDP [NASD]
CompanyIndaptus Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap18.48MEPS (ttm)-1.80
P/E-EPS this Y-9.83%
Forward P/E-EPS next Y8.95%
PEG-EPS past 5Y57.89%
P/S-EPS next 5Y-
P/B1.21EPS Q/Q-11.25%
Dividend-Sales Q/Q-
Insider Own31.38%Inst Own7.17%
Insider Trans0.00%Inst Trans12.85%
Short Float0.30%EarningsNov 06/a
Analyst Recom1.00Target Price12.00
Avg Volume9.93K52W Range1.50 - 4.08
Feb-15-24 08:00AM Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-08-24 08:00AM Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels (GlobeNewswire)
Jan-04-24 08:00AM European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology (GlobeNewswire)
Nov-06-23 04:01PM Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.20%
08:00AM Indaptus Therapeutics' Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study (GlobeNewswire)
Oct-31-23 09:01AM Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting (GlobeNewswire)
Sep-27-23 08:00AM Indaptus Therapeutics to Present at the LD Micro Main Event XVI (GlobeNewswire)
Sep-26-23 08:00AM Registration Is Now Open For Tribe Publics Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics CEO On Friday, September 29, 2023 (GlobeNewswire) +11.65%
Sep-19-23 08:00AM Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20 (GlobeNewswire) +7.34%
Sep-06-23 08:05AM Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson Glen R.10% OwnerAug 14Buy2.3423,93456,0061,190,400Aug 16 06:01 PM
Anderson Glen R.10% OwnerAug 11Buy2.1235,06474,3361,166,466Aug 16 06:01 PM
Anderson Glen R.10% OwnerAug 10Buy1.9444,35486,0471,131,402Aug 16 06:01 PM
15678910111213141520